Gilead Sciences has agreed to purchase the remainder of improvement accomplice Arcellx in a deal that values the biotechnology firm at about $7.8 billion at closing.
Source link
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Related Posts
Rohlik bets on tech and services as it plots its IPO in the cutthroat European online grocery market — TFN
Prague-based online grocery player Rohlik Group, which raised $170 million last June, reshapes the European grocery delivery landscape. Valued at…
AI Agent Security Is Recreating the Password Problem
AI brokers can flip momentary entry into an enduring safety legal responsibility throughout enterprise methods. The problem is controlling what…
3 Standout Tech Upgrades To Elevate the Home Office Experience
Mark Vena critiques three premium tech merchandise designed to enhance workflow, readability, and efficiency in a better house workspace. The…